Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Catalyst Pharmaceuticals (CPRX) EBITDA Margin: 2011-2025

Historic EBITDA Margin for Catalyst Pharmaceuticals (CPRX) over the last 7 years, with Sep 2025 value amounting to 35.55%.

  • Catalyst Pharmaceuticals' EBITDA Margin rose 145.00% to 35.55% in Q3 2025 from the same period last year, while for Sep 2025 it was 37.63%, marking a year-over-year increase of 662.00%. This contributed to the annual value of 33.34% for FY2024, which is 1541.00% up from last year.
  • Per Catalyst Pharmaceuticals' latest filing, its EBITDA Margin stood at 35.55% for Q3 2025, which was down 0.10% from 35.59% recorded in Q2 2025.
  • In the past 5 years, Catalyst Pharmaceuticals' EBITDA Margin ranged from a high of 41.91% in Q4 2022 and a low of -29.96% during Q3 2023.
  • Its 3-year average for EBITDA Margin is 28.70%, with a median of 34.62% in 2023.
  • Per our database at Business Quant, Catalyst Pharmaceuticals' EBITDA Margin slumped by 11,916bps in 2021 and then surged by 6,406bps in 2024.
  • Over the past 5 years, Catalyst Pharmaceuticals' EBITDA Margin (Quarterly) stood at 24.08% in 2021, then spiked by 1,783bps to 41.91% in 2022, then slumped by 1,040bps to 31.51% in 2023, then spiked by 797bps to 39.49% in 2024, then soared by 145bps to 35.55% in 2025.
  • Its EBITDA Margin was 35.55% in Q3 2025, compared to 35.59% in Q2 2025 and 40.06% in Q1 2025.